June 1, 2026 Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel ChangeSumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) today announced the following organizational change, change in the responsibilities of Executive Officer, and Personnel Change, effective July 1, 2026.
-
Organizational Realignment (effective July 1, 2026)
Corporate Departments
Vaccines and Adjuvants Business Development Office is established.
* To establish an organization that centrally oversees functions and activities related to the development of Vaccines and Adjuvants businesses, thereby putting in place a structure that enables strategic and agile operations.
-
Change in the responsibilities of Executive Officer (effective July 1, 2026)
Position as of July 1, 2026
Current position
Name
Managing Executive Officer Vaccines and Adjuvants Business Development,
Research and Development Division Senior Vice President, Head of Research and Development Division
Chief Development Officer, Sumitomo
Pharma America, Inc.
Managing Executive Officer Research and Development Division
Senior Vice President, Head of Research and Development Division
Chief Development Officer,
Sumitomo Pharma America, Inc.
Yumi Sato
- Change in Personnel (effective July 1, 2026)
Corporate Departments
Position as of July 1, 2026 | Current position | Name |
Vice President, Head of Vaccines and Adjuvants Business Development Office （VP, Global Head of Vaccines and Adjuvants R&D, Sumitomo Pharma America, Inc., effective August 1, 2026） | Senior Officer, Vaccines | Akihisa Fukushima |
1
Contact:
Corporate Communications Sumitomo Pharma Co., Ltd.
E-mail: prir@sumitomo-pharma.co.jp
2